Nanotherapy for Alzheimer's Disease and Vascular Dementia: Targeting Senile Endothelium

47 Pages Posted: 26 Sep 2017

Date Written: July 21, 2017

Abstract

Due to the complexity of Alzheimer's disease, multiple cellular types need to be targeted simultaneously in order for a given therapy to demonstrate any major effectiveness. Ultrasound-sensitive coated microbubbles (in a targeted lipid nanoemulsion) are available. Versatile small molecule drug(s) targeting multiple pathways of Alzheimer's disease pathogenesis are known. By incorporating such drug(s) into the targeted LCM/ND lipid nanoemulsion type, one obtains a multitasking combination therapeutic for translational medicine. This multitasking therapeutic targets cell-surface scavenger receptors (mainly SR-BI), making possible for various Alzheimer's-related cell types to be simultaneously searched out for localized drug treatment in vivo. Besides targeting cell-surface SR-BI, the proposed LCM/ND-nanoemulsion combination therapeutic(s) include a characteristic lipid-coated microbubble [LCM] subpopulation (i.e., a stable LCM suspension); such film-stabilized microbubbles are well known to substantially reduce the acoustic power levels needed for accomplishing temporary noninvasive (transcranial) ultrasound treatment, or sonoporation, if additionally desired for the Alzheimer's patient.

Keywords: Alzheimer's Disease, Dementia, Drug Targeting, Nanoemulsion, Scavenger Receptors, Sonoporation

Suggested Citation

D'Arrigo, Joseph, Nanotherapy for Alzheimer's Disease and Vascular Dementia: Targeting Senile Endothelium (July 21, 2017). Available at SSRN: https://ssrn.com/abstract=3041744 or http://dx.doi.org/10.2139/ssrn.3041744

Register to save articles to
your library

Register

Paper statistics

Downloads
22
Abstract Views
206
PlumX Metrics